| Antigen |
Clone |
| Haemoglobin scavenger receptor (CD163) |
GHI/61 |
| Hairy (Drosophila)
|
1/24 |
| Hairy (Drosophila)
|
3/30 |
| Hapatitis B Surface Antigen |
1023 and 1025 |
| Hepatocyte Growth Factor/Scatter
Factor (HGF/SF) |
EGH2 4C12.1 |
| Hepatocyte Growth Factor/Scatter
Factor (HGF/SF) |
SBF5 C1.7 |
| Herpes Simplex Virus
protein ICP8 |
10A3 |
| Herpes Simplex Virus
protein ICP8 |
11E2 |
| Herpes
Simplex Virus protein UL42 |
13C9 |
| Herpes
Simplex Virus protein UL42 |
13D11 |
| Herpes
Simplex Virus protein UL42 |
2H4 |
| HIF1 alpha |
ESEE122 |
| HIF1 alpha |
Ha111a |
| HIF1 alpha |
Hif28b |
| HIF2 alpha |
EP190b |
| HIF2 alpha |
Hif2a 237 |
| HLA-associated invarient chain (CD74) |
By2 |
| HLA-A2 |
BB7.2 |
| HLA-D/DR, DQ |
35 |
| HLA-DM |
TAL 18.1 |
| HLA-DPw4 and DPw2 |
DP 11.1 |
| HLA-DP alpha |
TAL 3C3 |
| HLA-DQ1 |
TAL 4.1 |
| HLA-DQ3 |
2HB6 |
| HLA-DQ3, DQ4 and DR4 |
TAL 12.1 |
| HLA-DQW1 |
Genox 3.53 |
| HLA-DR |
CR/43 |
| HLA-DR |
LHM 4 |
| HLA-DR |
TAL 15.1 |
| HLA-DRβ 1st domain
and DP |
TAL 14.1 |
| HLA-DRβ chain
1 (1st domain, monomorphic) |
DA2 |
| HLA-DRβ chain |
TDR 31.1 |
| HLA-DR16, 103, 11,
12, 13, 8, 7, 4 (Dw10 only), DR51 (DR15 associated). |
TAL 16.1 |
| HLA-DR3, 6, 1, J25
|
TAL 8.1 |
| HLA-DR7, DRβ1
domain. |
TAL 13.1 |
| HLA-DRα |
TAL 1B5 |
| HPV-1 E4 |
4.37E4 |
| HPV-16 E1/E4 |
TVG 403 |
| HPV-16 E2 |
TVG 261 |
| HPV-16 E2 |
TVG 271 |
| HPV-16 E6 and HPV-18
E6 |
C1P5 |
| HPV16 E7 |
TVG 701Y |
| HPV-16 L1 |
CamVir 1 |
| HPV-18 E6 |
BF7 |
| HRX |
HRX107 |
| Human ACF1 BAZIA |
hACF1 BAZIA |
| Human Factor IX |
RFF-IX/1 |
| Human Factor VII |
RFF-VII/1 |
| Human Factor VII |
RFF-VII/2 |
| Human Factor VIII |
RFF-VIII:c/8 |
| Human Factor VIII:c heavy chain |
RFF-VIII:c/6 |
| Human Factor VIII:c light chain |
RFF-VIII:c/5 |
| Human Milk Fat Globule, MUC1 |
HMFG1 |
| Human Spasmolytic Polupeptide |
HSP GE16c |
| Human Von Willebrand Factor (VWF) |
RFF-VIII:R/1 |
| Human Von Willebrand Factor (VWF) |
RFF/VIII:R/2 |
For further information about antibodies from CRT or to discuss sales or licensing options, please contact us at reagents@cancertechnology.com
Please note that CRT supplies to distributors only. However, we are happy to direct researchers to the appropriate commercial party to obtain antibodies within our portfolio. Click here to view disclaimer information. |
